Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC sequencing data of 2102EP, VM-CUB-1, Caki-1 and DU-145 cells treated with epigenetic agent LAK31 (2102EP additionally: Romidepsin, Quisinostat and MZ-1) and DMSO as solvent control

ABSTRACT: ATAC sequencing data of cell lines of urological malignancies treated with epigenetic agents LAK31, Romidepsin, Quisinostat and MZ-1.

ORGANISM(S): Homo sapiens

PROVIDER: GSE191184 | GEO | 2022/09/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNA sequencing data of 2102EP, VM-CUB-1, Caki-1 and DU-145 cells treated with epigenetic agent LAK31 and DMSO as solvent control

Project description:RNA sequencing data of cell lines of urological malignancies treated with the epigenetic agent LAK31 or DMSO as solvent control.

2022-09-01 | GSE190022 | GEO

RNA sequencing data of 2102EP cells treated with epigenetic agents Quisinostat, JIB-04, Chaetocin, MZ-1, LP99, PRT4165 and GSK343 and DMSO as solvent control

Project description:Single end 3' RNA sequencing of embryonal carcinoma cell line 2102EP treated with epigenetic agents Quisinostat, JIB-04, Chaetocin, Mz-1, LP99, PRT4165 and GSK343. DMSO was used as solvent control. Cells were treated with the epi-drugs for 16 h.

2022-01-21 | GSE189472 | GEO

Expression data of Panc1 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.

2021-08-21 | GSE182526 | GEO

ChIP-seq. analysis of pan-histone 3 acetylation in Romidepsin treated TCam-2

Project description:ChIP-seq. analysis of TCam-2 16 h after 10 nanomolar Romidepsin application. DMSO treated cells were used as controls. For ChIP, an antibody against histone H3 pan-acetylation was used. These data are part of the article 'The Histone Deacetylase Inhibitor Romidepsin Efficiently Targets Cisplatin-resistant Germ Cell Cancer Cells via Downregulation of the SWI/SNF-Complex Member ARID1A' (Nettersheim et al., 2016). TCam-2 cells treated for 16h with romidepsin or the solvent were fixed by formaldehyde solution and further processed by Active Motif, including DNA shearing by sonication, chromatin-immunoprecipitaion, library generation and sequencing (NextSeq 500, Illumina). Pooled input DNA of each sample including spike-in Drosophila DNA was used as controls and for normalization. The 75-nt sequence reads were mapped against the genome using BWA algorithm. Duplicate reads were removed. Only peaks that align with no more than 2 mismatches and map uniquely to the genome were used for further analysis. Intervals / peaks were identified by the MACS peak finding algorithm (cutoff p-value 1x10-7) including ENCODE blacklist filtering

2016-09-01 | E-GEOD-78262 | biostudies-arrayexpress

Expression data of MOLT-4 cells treated with romidepsin and tamoxifen

Project description:Tamoxifen enhaces romidepsin-induced apoptosis in T-cell malignant cells. We compared gene-expression profile among untreated control, romidepsin-treted,

2020-02-21 | GSE145606 | GEO

Effect of Romidepsin treatment on patient-derived liver cancer cells

Project description:Romidepsin displayed potent antitumor activity in our lenvatinib-resistant PDCs, we wanted to investigate the underlying mechanism of how romidepsin initiated susceptibility to conquer lenvatinib resistance in liver cancer.

2024-03-17 | GSE227751 | GEO

Quantitative RNAseq Analysis of Treatment Outcomes with Talazoparib, Romidepsin or Combination in MBL2 cell line

Project description:To explore the molecular mechanisms by which romidepsin potentiates the effect of talazoparib, RNA sequencing analysis of MBL2 cell lines treated with talazoparib, romidepsin, or talazoparib plus romidepsin was performed. 40% of the 2023 genes in combination were from talazoparib, whereas only 5.9% of the genes deregulated during the treatment with the combination of talazoparib plus romidepsin were from the effect of romidepsin. 94 genes were presented in all three treatment groups and included upregulation of Prdm1, Dusp5, and CD74, among others. Analysis of genes responsible for DNA repair, cell cycle arrest and apoptosis demonstrated the contribution of romidepsin to downregulation of DNA repair, the synergistic effect of romidepsin and talazoparib on downregulation of genes of cell cycle leading to cell cycle arrest, and activation of apoptosis by talazoparib predominantly.

2020-09-04 | GSE157434 | GEO

RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

Project description:RNA sequencing of BM-derived senescent MDSCs treated or not with Romidepsin

2023-03-02 | GSE199921 | GEO

Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

Project description:Nascent RNA sequencing (PRO-seq) after 200nM romidepsin treatment of H9 cells

2019-12-12 | GSE141843 | GEO

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Project description:This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

| 2106666 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data